Dr. Bauml Discusses the FLAURA Study in NSCLC

September 19, 2017
Joshua Bauml, MD

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non–small cell lung cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non—small cell lung cancer (NSCLC).

FLAURA is a randomized phase III study of frontline osimertinib (Tagrisso) compared with either erlotinib (Tarceva) or gefitinib (Iressa).

Results showed an improvement in progression-free survival, and a trend was observed toward overall survival with osimertinib—though it is not yet statistically significant.

x